- Home
- » Tags
- » Saxagliptin
Top View
- Insulin Glargine and Detemir Pioglitazone Exenatide Liraglutide
- Clinical Review Hyon Kwon, Pharmd, MPH Snda 208751/S-010 and S-011 Fiasp (Insulin Aspart)
- Sodium-Glucose Cotransporter 2 Inhibitors
- Role of Saxagliptin As Monotherapy Or Adjunct Therapy in the Treatment of Type 2 Diabetes
- QTERN (Dapagliflozin and Saxagliptin) Is Indicated As an Adjunct to Diet and Exercise to Improve Glycemic Control in Adults with Type 2 Diabetes Mellitus
- ONGLYZA (Saxagliptin) Tablets, for Oral Use Common in Patients Treated with ONGLYZA Than in Patients Treated Initial U.S
- PRAC Concludes That Diabetes Medicine Canagliflozin May Contribute to Risk of Toe Amputation Risk May Also Apply to Other Medicines in the Same Class
- Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
- Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
- Saxagliptin and Alogliptin Safety Communication
- Sodium-Glucose Cotransporter-2 Inhibitors
- DIALOGUE STARTS BMJ Questions (About Exenatide. but Reply Includes
- Diabetes Management Medications
- (Qtern), Dapagliflozin/Saxagliptin/Metformin (Qternmet
- (DPP-4) Inhibitors Be Avoided in Patients with Heart Failure?
- Insulin Degludec/Insulin Aspart (Degludecplus) for Type 2 Diabetes
- Saxagliptin-Dapagliflozin (Qtern)
- ONGLYZA in Patients These Highlights Do Not Include All the Information Needed to Use Who Have Known Risk Factors for Heart Failure
- Qtrilmet, INN-Metformin, Saxagliptin and Dapagliflozin
- Attachment 1. Product Information for Saxagliptin / Metformin Hydrochloride
- Renoprotective Effects of DPP-4 Inhibitors
- Onglyza, INN-Saxagliptin
- Step Therapy
- Comparison Chart of Glucose-Lowering Agents For
- Qtern, INN-Saxagliptin and Dapagliflozin
- (Saxagliptin and Metformin Hcl Extended-Release) KOMBIGLYZE XR Can Cause Serious Side Effects, Including Lactic Acidosis
- The Future of Insulin Therapy for Patients with Type 2 Diabetes Mellitus Joseph M
- Therapeutic Class Review Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Package Leaflet: Information for the Patient Onglyza® 2.5 Mg Film
- When Counselling on Or Filling Prescriptions for Insulin, Do You See Patients Taking More Than 20 Units of Rapid-Acting Insulin a Day?
- Risk Assessment and Risk Mitigation Review(S)
- SIGN 116 SMC Advice (At April 2011)
- Letter Regarding AHA Scientific Statement “Drugs That May Cause Or Exacerbate Heart Failure”
- CDR Pharmacoeconomic Review Report on Onglyza (Saxagliptin)
- FDA Warns That DPP-4 Inhibitors for Type 2 Diabetes May Cause Severe Joint Pain
- Original Article the Efficacy of Treating Newly Diagnosed Type 2 Diabetes
- Saxagliptin) Tablets
- Qtrilmet, INN-Metformin, Saxagliptin and Dapagliflozin
- Saxagliptin and Metformin
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- Antihyperglycemic Agents Comparison Chart
- Latest Advances in the Management of Diabetes
- A Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With
- Download an Informational Brochure About
- Saxagliptin and Metformin for Diabetes
- 209196Orig1s000
- FDA Drug Safety Communication: FDA Adds Warnings About Heart Failure Risk to Labels of Type 2 Diabetes Medicines Containing Saxagliptin and Alogliptin
- QTERNMET XR Safely and Effectively
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes